Study Title

A Phase 1 Study of JNJ-69086420, an Actinium-225-Labeled Antibody Targeting Human Kallikrein-2 (hK2) for Advanced Prostate Cancer

Study Details

Description:

The purpose of this study is to determine the recommended Phase 2 dose(s) (RP2D[s]) of JNJ-69086420 in Part 1 (Dose Escalation) and to determine safety and and preliminary signs of clinical activity at the RP2D(s) in Part 2 (Dose Expansion).

Sponsor:

Janssen Pharmaceuticals

Contacts:

Study Contact

participate-in-this-study@its.jnj.com

844-434-4210

© 2021 XCancer Software LLC

Contact XCancer: 402-991-8468